The Intravitreal Ivt Injectable Market to grow at a CAGR of 4.9% between 2022-2028

The Intravitreal Ivt Injectable Market is bound to reach US$ 23,814.3 Mn at a CAGR of 4.9% between 2018-2028. The current scenario is such that on-demand healthcare storage is being asked for. Cloud computing thus curtails operational expenses and capital as it simplifies sharing medical records, creates and maintains telehealth apps, and automates backend operations. This would be the scene with the healthcare vertical in the upcoming period.

According to the most recent Persistence Market Research (PMR) report, the Intravitreal (IVT) Injectables Market will grow at a CAGR of 4.9% between 2022 and 2028, surpassing US$ 23,814.3 million in terms of market value.

Growing retinal diseases are expected to boost the global intravitreal injectable market at a substantial rate over the forecast period. Millions of people are affected by retinal disorders, which commonly result in vision loss or complete blindness. Intravitreal injection is a safe and easy method of treating retinal disorders.

Get Sample Copy of this Report@

Company Profiles:

  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals, Inc.
  • Bausch & Lomb
  • Novartis AG
  • Allergan
  • Alimera Sciences
  • ThromboGenics, Inc.
  • Bristol-Myers Squibb Company


Request for Methodology@

According to the National Eye Institute (NEI), around 2.0 million people in the United States were afflicted by AMD in 2010, with the figure anticipated to more than increase to 5.4 million by 2050. To address rising demand, industry players are focused on innovation by developing a solid pipeline of IVT injections for the treatment of retinal diseases.

Between 2022 and 2028, North America is expected to account for a significant share of the global market. Increased incidence of age-related macular degeneration (AMD) is expected to stimulate demand for intravitreal (IVT) injectables in the United States.

Due to an increase in the elderly population and an increase in the incidence of retinal illnesses, the European market is also expected to fuel market growth. In the coming years, countries such as India and China are likely to boost demand for intravitreal (IVT) injectables in the Asia Pacific region, due to the presence of a sizable patient pool suffering from diabetes mellitus.

Want More Insights?

PMR has presented a comprehensive report based on Intravitreal (IVT) Injectable Market as per Indication (Diabetic Retinopathy, Macular Degeneration, Endophthalmitis, Retinal Vein Occlusions and Others), Drug Class (Anti-VEGF, Corticosteroids, Antibiotics, Antivirals and Antifungals), Distributional Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies and Others), based on seven regions.

Access Full Report@

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales –

Comments are closed